Turn Therapeutics Inc. cash flow to debt ratio of -3.19K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Turn Therapeutics Inc.'s free cash flow has decreased 85.92% from $-1.46M last year to $-2.72M, signaling decreasing performance

Turn Therapeutics Inc.'s debt to equity ratio is 0.98, which means that the company's assets are unhealthy financed, signaling financial risk.

Turn Therapeutics Inc.'s debt has increased relative to shareholder equity from -0.68 last year to 0.98 today, signaling weakened financials

Turn Therapeutics Inc. has a net cash position, so leverage is healthy.

Turn Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Turn Therapeutics Inc. has insufficient data to evaluate this check.

Turn Therapeutics Inc.'s short-term liabilities of $6.00M exceed its short-term assets of $5.20M, signaling financial risk

Turn Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Turn Therapeutics Inc.'s return on equity of -116.83%, is lower than 15.00%, indicating bad performance

Turn Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Turn Therapeutics Inc. has insufficient public price history to evaluate earnings stability.

Turn Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Turn Therapeutics Inc. has negative free cash flow, indicating cash burn

Turn Therapeutics Inc.'s yearly earnings has decreased 80.62% since last year from $-1.77M to $-3.19M, signaling decreasing performance

Turn Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -49.55% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Turn Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Turn Therapeutics Inc. has insufficient public price history to evaluate revenue consistency.

Turn Therapeutics Inc. has insufficient public price history to evaluate ROE consistency.

Turn Therapeutics Inc. has insufficient data to evaluate this check.

Turn Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Turn Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Turn Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Turn Therapeutics Inc. has insufficient data to evaluate this check.

Turn Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Turn Therapeutics Inc. has a price-to-book ratio of 46.27x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Turn Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue